Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Listed on the ASX and Nasdaq under the ticker TLX. You are encouraged to report negative side effects of prescription drugs to the FDA.

Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations

in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing [email protected]. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

05/06/2026

Glioblastoma is the most common and aggressive primary brain cancer, with no new treatment options and little improvement in outcomes over the past 20 years.

As featured on Channel Nine National News tonight, Telix’s IPAX BrIGHT Phase 3 study is evaluating a new targeted radionuclide therapy approach for patients, like Joe, who are suffering from recurrent disease.

Now recruiting at Gold Coast University Hospital, Austin Health in Melbourne and multiple European sites, the study is assessing TLX101-Tx (¹³¹I-iodofalan) in combination with chemotherapy, compared to chemotherapy alone.

IPAX BrIGHT builds on promising earlier research from the IPAX series of studies and marks an important step in advancing this product candidate towards registration, where there is such critical unmet need.

Learn more about the trial here https://clinicaltrials.telixpharma.com/trial/ipax-bright/

TLX101-Tx has not received a marketing authorization in any jurisdiction.

Telix has announced a strategic research collaboration with United Imaging Healthcare North America, focused on advancin...
02/06/2026

Telix has announced a strategic research collaboration with United Imaging Healthcare North America, focused on advancing integrated theranostics solutions.

The collaboration will explore how United Imaging’s advanced scanner platforms, software and AI capabilities can be combined with Telix’s molecular imaging portfolio and clinical protocols to support seamless, standardized and data-driven theranostic workflows.

Initial efforts will focus on TLX101-Px (Pixclara®, Floretyrosine F 18) in the U.S., with the potential to expand into additional products, candidates and markets over time.

Learn more about the announcement here: https://telixpharma.com/news-views/telix-and-united-imaging-announce-strategic-theranostics-collaboration/

TLX101-Px has not received a marketing authorization in any jurisdiction. Brand name subject to final regulatory approval.

Data from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (lutetium-177 rosopatamab tetraxetan) in patient...
01/06/2026

Data from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (lutetium-177 rosopatamab tetraxetan) in patients with PSMA-positive metastatic castration-resistant prostate cancer, have been presented as a late-breaking oral presentation at ASCO 2026.

The data demonstrated an acceptable safety and tolerability profile for TLX591-Tx when administered with contemporary standard-of-care therapies, with no new safety signals observed.

These findings support further evaluation of TLX591-Tx in the randomized phase of the study, which is actively dosing patients in jurisdictions where health authority approval has been granted.

Swipe to read more from Principal Investigator Pedro C. Barata, MD, and Telix Group Chief Medical Officer David N. Cade, MD.

Click here to read more about the full results: https://telixpharma.com/news-views/prostact-global-phase-3-part-1-data-presented-in-late-breaking-oral-session-at-asco-2026/

TLX591-Tx has not received a marketing authorization in any jurisdiction.

This Pride Month, we’re reflecting on work that continues year‑round: creating a workplace where everyone feels respecte...
31/05/2026

This Pride Month, we’re reflecting on work that continues year‑round: creating a workplace where everyone feels respected, supported, and included.​

This commitment is grounded in our value of Everyone Counts. We know people do their best work when they feel safe to speak up, share perspectives, and be themselves. ​

We continue to learn, listen, and improve together, guided by respect for one another and a shared focus on our purpose to help people with cancer and rare diseases live longer, better quality lives.​

29/05/2026

When Craig Stankiewicz was diagnosed with glioblastoma, one of the most difficult moments was telling his daughters he had cancer.

But his youngest daughter’s response surprised him: “Everybody has a superhero inside of them. It’s time for yours to go to work.”

Since then, Craig has navigated surgery, radiation, chemotherapy and two years of TTFields therapy, while raising two daughters with his wife Emily by his side at every step.

Nearly five years on, Craig is sharing his story to help others facing one of the most difficult diagnoses in oncology.

During Brain Tumor Awareness Month, Telix is sharing stories from patients, caregivers and advocates working to improve the lives of those affected by brain cancer.

Visit headforthecure.org for educational resources, information on fund-raising initiatives and patient communities.

U.S. healthcare professionals can explore diagnostic challenges in glioma at: gliomagrayareas.com

For more on Telix’s brain cancer portfolio, visit: telixpharma.com/brain

28/05/2026

Data from Part 1 of the ProstACT Global Phase 3 study will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting, taking place this week in Chicago.

In this video, Pedro Barata, MD, MSc, discusses the trial, which is evaluating TLX591-Tx, Telix’s PSMA-targeted lutetium radio antibody-drug conjugate therapy candidate, in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

Part 1 of the study was a safety and dosimetry lead-in, assessing the tolerability, biodistribution and radiation dose profile of TLX591-Tx when administered in combination with standard of care.

Learn more about our presence at ASCO here: https://telixpharma.com/telix-at-asco-2026/



TLX591-Tx has not received a marketing authorization in any jurisdiction.

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.ASCO 2026 will feature a late-breaking ora...
28/05/2026

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.

ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (177Lu-rosopatamab tetraxetan) in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

The presentation will be delivered by Pedro Barata, MD, MSc, on Monday, June 1.

Telix’s renal cancer therapeutics program will also be featured at ASCO, with a poster presentation on LUTEON, a Phase 2/3 study evaluating TLX250-Tx (177Lu-girentuximab) in advanced relapsed or recurrent clear cell renal cell carcinoma.

Swipe to view the presentation details and follow the link to learn more: https://telixpharma.com/telix-at-asco-2026/

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.This year’s program features seven abstracts from ac...
27/05/2026

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.

This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.

Poster presentations will also cover prostate cancer imaging (BiPASS™), kidney cancer therapy (LUTEON), recurrent glioblastoma therapy (IPAX BrIGHT), and discovery-stage radiopharmaceutical science.
Meet us at Booth #745 to connect with and learn more about our theranostic pipeline, commercial portfolio and manufacturing capabilities.

Swipe to view the presentation details and follow the link to learn more: https://telixpharma.com/telix-at-snmmi-2026/

Join Telix’s Managing Director and Group CEO, Dr. Christian Behrenbruch, at two upcoming investor conferences in the Uni...
27/05/2026

Join Telix’s Managing Director and Group CEO, Dr. Christian Behrenbruch, at two upcoming investor conferences in the United States.

Dr. Behrenbruch will participate in the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference to discuss Telix’s growing commercial business, late-stage theranostic pipeline and global leadership in radiopharmaceuticals.

Learn more: https://telixpharma.com/news-views/telix-to-participate-in-william-blair-growth-stock-and-jefferies-global-healthcare-conferences/

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category